% | C57Bl/6J | LDLR-/-ApoB100/100 | IGF-II/LDLR-/-ApoB100/100 |
---|---|---|---|
ΔHR | 13.22 ± 8.45 (0.043) | 6.19 ± 6.52 (0.070) | 9.86 ± 4.93 (0.011) |
ΔEF | 14.87 ± 4.51 (0.001) | 16.83 ± 1.52 (< 0.0001) | 16.79 ± 8.53 (0.001) |
ΔFS | 15.48 ± 6.00 (0.005) | 11.91 ± 2.18 (0.003) | 13.74 ± 7.44 (0.0145) |
ΔLVIDED | -9.4 ± 4.5 (0.009) | -12.7 ± 6.7 (0.016) | -9.3 ± 3.7 (0.032) |
ΔLVIDES | -31.9 ± 11.1 (0.002) | -24.6 ± 6.8 (0.001) | -24.9 ± 13.0 (0.017) |
ΔLVPW;d | 18.0 ± 2.9 (0.099) | 19.6 ± 8.4 (0.006) | 18.5 ± 11.3 (0.021) |
ΔLVPW;s | 37.4 ± 19.1 (0.184) | 29.7 ± 7.9 (0.0004) | 28.3 ± 13.9 (0.004) |
ΔLVAW;d | 26.7 ± 22.0 (0.863) | 23.0 ± 25.7 (0.078) | 28.0 ± 12.0 (0.005) |
ΔLVAW;s | 32.3 ± 10.9 (0.001) | 26.6 ± 15.6 (0.010) | 28.0 ± 16.6 (0.004) |
ΔLV Vol;d | -20.5 ± 9.6 (0.009) | -25.5 ± 14.1 (0.012) | -20.7 ± 7.6 (0.006) |
ΔLV Vol;s | -61.1 ± 16.8 (0.002) | -50.0 ± 12.0 (0.002) | -51.6 ± 19.2 (0.012) |
Values denote mean ± SD. Dobutamine challenge was performed to 5 (LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100) or 6 mice (C57Bl/6J) per strain. P-values from paired t-test comparing group baseline and the maximal response after dobutamine are shown in parenthesis. |